EA
PVLA

Emerald Advisers’s Palvella Therapeutics PVLA Stock Holding History

Emerald Advisers’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.1M Buy
229,486
+67,986
+42% +$8.25M 0.83% 50
2026
Q1 		$20.1M Buy
+161,500
New +$16.8M 0.64% 68
2016
Q1 		– Sell
-702
Closed -$129K – 336
2015
Q4 		$129K Buy
702
+49
+8% +$8.23K 0.01% 311
2015
Q3 		$96K Hold
653
– – 0.01% 325
2015
Q2 		$144K Buy
+653
New +$144K 0.01% 312

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Emerald Advisers's PVLA Position: Q2 2026 in Review

Emerald Advisers increased its Palvella Therapeutics (PVLA) stake by 42% in Q2 2026, buying an estimated $8.25M and bringing the position to 229,486 shares worth $35.1M. The position accounts for 0.83% of the portfolio, ranked #50.

Emerald Advisers first reported a position in PVLA in Q2 2015 and has held it in 5 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Emerald Advisers held 229,486 shares of Palvella Therapeutics worth $35.1M as of Q2 2026.
  • Emerald Advisers bought 67,986 Palvella Therapeutics shares in Q2 2026, an estimated $8.25M.
  • Palvella Therapeutics made up 0.83% of Emerald Advisers's portfolio in Q2 2026, its #50 holding.
  • Emerald Advisers first reported a position in Palvella Therapeutics in Q2 2015 and has held it in 5 quarters since.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Emerald Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.